Table 1. Choice of lymphoma antigen for CAR-T cell targeting .
| CAR Configuration | Target Antigen | Co-stimulatory Domain | Pathology/Disease | Outcome | Ref. |
| CD19-4-1BB-CD3ζ | CD19 | 4-1BB | B Cell Lymphoma | CR: 3/20 PR: 1/20 | 41 |
| CD19-CD28-CD3ζ | CD19 | CD28 | CR: 1/8; PR: 5/8; SD: 1/8 | 42,43 | |
| CD19-CD28-CD3ζ | CD19 | CD28 | CR: 8/15; PR: 4/15; SD: 1/15 | 44 | |
| CD19-CD28-CD3ζ | CD19 | CD28 | CR: 1/9; PR: 5/9 | 45 | |
| CD20-CD3ζ | CD20 | None | CR: 2/7; PR: 1/7; SD: 4/7 | 46 | |
| CD19-CD3ζ | CD19 | None | CR: 7/16; PR: 4/16 | 47 | |
| CD20-4-1BB-CD3ζ | CD20 | 4-1BB | CR: 3/6; PR: 1/6 | 48 | |
| k-Light Chain- CD3ζ | k-light chain | None | CR: 2/10; PR: 3/10 | 38 | |
| CD30-4-1BB-CD3ζ | CD19/CD30 | 4-1BB | HL/ALCL | CR: 1/6; PR: 3/6; PD: 2/6 | 49 |
| CD19-4-1BB-CD3ζ | CD19 | 4-1BB (CD137) | Lymphoma | - | 28 |
| CD19-CD28-CD3ζ | CD19 | CD28 | |||
| CD19-CD28-CD3ζ | CD19 | CD28 | |||
| CD19-CD28-CD3ζ | CD19 | CD28 | |||
| CD19-CD28-CD3ζ | CD19 | CD28 | |||
| CD19-CD28-4-1BB-CD3ζ | CD19 | CD28 and 4-1BB | |||
| CD19-CD28-CD3ζ | CD19 | CD28 | Acute Non-Chronic Lymphoma | CR: 6/20, PR: 2/20 | 50,51 |
| CD19-CD28-CD3ζ | CD19 | CD28 | B Cell Lymphoma | CR: 3/8, PR: 1/8 | 51,52 |
| CD19-CD28-CD3ζ | CD19 | CD28 | Acute and Chronic Lymphoma | CR: 11/19 | 51,53 |
| CD19-4-1BB-CD3ζ | CD19 | 4-1BB | Acute Lymphoma | CR:1/2 | 34,51 |
| CD19-CD28/CD137/CD27-CD3ζ | CD19 | CD28/CD137/CD27 | Acute Lymphoma | CR:4/6 | 51,54 |
| CD19/CD20-CD3ζ | CD19/CD20 | None | FL/DLBCL | RR: 2/4, CR: 2/4 | 35 |
| CD19-CD28-CD3ζ | CD19 | CD28 | SLL/TFL/PCNSL/ DLBCL | RR: 0/6, CR: 0/6 | 55 |
| CD19-CD28-CD3ζ | CD19 | CD28 | FL/SMZL | RR: 4/5, CR: 0/5 | 43 |
| CD20-CD28-4-1BB-CD3ζ | CD20 | CD28 and 4-1BB | MCL/FL | RR: 3/3, CR: 2/3 | 56 |
| CD20-4-1BB-CD3ζ | CD20 | 4-1BB | DLBCL | RR: 5/7, CR: 1/7 | 48 |
| CD19-CD28-CD3ζ | CD19 | CD28 | SMZL/PMBCL/DLBCL/low-grade NHL | RR: 8/11, CR: 5/11 | 44 |
| CD19-CD28-CD3ζ | CD19 | CD28 | DLBCL/MCL/TFL | RR: 2/10, CR: 1/10 | 50 |
| k-Light Chain-CD28-CD3ζ | k-Light Chain | CD28 | DLBCL/MCL/TFL/LPL | RR: 3/7, CR: 2/7 | 38 |
| CD19-CD28-CD3ζ | CD19 | CD28 and 4-1BB | LBCL/TFL.MCL/FL | RR: 19/30, CR: 10/30 | 47 |
| CD20-CD28-CD3ζ/ CD19-CD3ζ | CD19 | None/ CD28 | DLBCL/MCL | RR: 15/16, CR: 13/16 | 57 |
| CD20-4-1BB-CD3ζ | CD20 | 4-1BB | DLBCL/FL/MCL/PCMZL | RR: 9/11, CR: 6/11 | 58 |
| CD19-CD28-CD3ζ | CD19 | CD28 | DLBCL/FL/PMBCL/MCL | RR: 16/22, CR: 12/22 | 45 |
| CD19-CD28-CD3ζ | CD19 | CD28 | DLBCL | RR: 5/7, CR: 4/7 | 59 |
| CD19-CD28-CD3ζ | CD19 | CD28 | DLBCL/FL/PMBCL | RR: 83/101, CR: 55/101 | 60 |
| CD19-CD28-CD3ζ | CD19 | CD28 | DLBCL/FL | RR: 18/28, CR: 16/28 | 29 |
| CD19-CD28-4-1BB-CD3ζ | CD19 | CD28 and 4-1BB | DLBCL/MCL/FL | RR: 3/9, CR: 3/9 | 61 |
| CD19-CD28-4-1BB-CD3ζ | CD19 | CD28 and 4-1BB | DLBCL/SLL/BCLU | RR: 9/13, CR: 7/13 | 62 |